Loading
Life sciences · Observational Study
ClinicalTrials.gov · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07850765). This is a study registration, not published results. Lead sponsor: Novo Nordisk A/S. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 1260 participants (ACTUAL). Conditions: Overweight, Obesity. Interventions: DRUG: Semaglutide. Primary outcome measures: Change in Food Noise Questionnaire (FNQ) score , At data capture (Day 1); Change in Body Weight , At data capture (Day 1); Health-Related Quality of Life Measured by EQ-5D-5L , At data capture (Day 1); Health Status Measured by EQ Visual Analogue Scale (EQ-VAS) , At data capture (Day 1); Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ) , At data capture (Day 1); Number of Participant Satisfaction With Wegovy , At data capture (Day 1); Change in Body Mass Index (BMI) , At data capture (Day 1); Percent Change in Body Weight , At data capture (Day 1); Number of Participants with Achievement of Weight-Loss Target , At data capture (Day 1); Number of Participants who Concern About Future Weight Gain , At data capture (Day 1); Impact of Wegovy on Weight-Related Burden , At data capture (Day 1); Impact of Wegovy on Daily Life and Health Behaviours , At data capture (Day 1). Brief summary: The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.